Stock Track | CHINARES PHARMA Plummets 5.02% Intraday on Subsidiary's Profit and Revenue Decline

Stock Track04-27 11:00

CHINARES PHARMA's stock price plummeted 5.02% during intraday trading on Monday, following the release of weak financial results from its subsidiary.

The sharp decline came after China Resources Pharmaceutical, the parent company, filed a disclosure showing that its subsidiary China Resources Double-Crane Pharmaceutical reported a year-on-year decrease in both profit and revenue for the first quarter of 2026.

According to the filing, the subsidiary's net profit fell to 501.4 million yuan from 522.7 million yuan a year earlier, while revenue declined to 2.81 billion yuan from 3.08 billion yuan in the prior year period, indicating weaker operational performance.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1100587736?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-27 11:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1100587736","market":"sg","top_or_hot":-1,"title":"Stock Track | CHINARES PHARMA Plummets 5.02% Intraday on Subsidiary's Profit and Revenue Decline","media":"Stock Track","content":"<p>CHINARES PHARMA's stock price plummeted 5.02% during intraday trading on Monday, following the release of weak financial results from its subsidiary.</p><p>The sharp decline came after China Resources Pharmaceutical, the parent company, filed a disclosure showing that its subsidiary China Resources Double-Crane Pharmaceutical reported a year-on-year decrease in both profit and revenue for the first quarter of 2026.</p><p>According to the filing, the subsidiary's net profit fell to 501.4 million yuan from 522.7 million yuan a year earlier, while revenue declined to 2.81 billion yuan from 3.08 billion yuan in the prior year period, indicating weaker operational performance.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | CHINARES PHARMA Plummets 5.02% Intraday on Subsidiary's Profit and Revenue Decline</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | CHINARES PHARMA Plummets 5.02% Intraday on Subsidiary's Profit and Revenue Decline\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-04-27 11:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>CHINARES PHARMA's stock price plummeted 5.02% during intraday trading on Monday, following the release of weak financial results from its subsidiary.</p><p>The sharp decline came after China Resources Pharmaceutical, the parent company, filed a disclosure showing that its subsidiary China Resources Double-Crane Pharmaceutical reported a year-on-year decrease in both profit and revenue for the first quarter of 2026.</p><p>According to the filing, the subsidiary's net profit fell to 501.4 million yuan from 522.7 million yuan a year earlier, while revenue declined to 2.81 billion yuan from 3.08 billion yuan in the prior year period, indicating weaker operational performance.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"03320","symbol_name":"华润医药","start_time":0,"source_url":"","article_id":"1100587736","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1100587736","pubTimestamp":1777258833,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"CHINARES PHARMA's stock price plummeted 5.02% during intraday trading on Monday, following the release of weak financial results from its subsidiary.The sharp decline came after China Resources...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"03320":"华润医药"},"translate_title":"个股赛道|子公司利润营收双降CHINARES PHARMA盘中暴跌5.02%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03320":1},"content_text":"CHINARES PHARMA's stock price plummeted 5.02% during intraday trading on Monday, following the release of weak financial results from its subsidiary.The sharp decline came after China Resources Pharmaceutical, the parent company, filed a disclosure showing that its subsidiary China Resources Double-Crane Pharmaceutical reported a year-on-year decrease in both profit and revenue for the first quarter of 2026.According to the filing, the subsidiary's net profit fell to 501.4 million yuan from 522.7 million yuan a year earlier, while revenue declined to 2.81 billion yuan from 3.08 billion yuan in the prior year period, indicating weaker operational performance.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1100587736","isCrawlerRequest":true}